With over expected 8,000 visitors in the next three days, Vitafoods India 2025 continues to solidify its position as a leading networking and knowledge-sharing hub for the nutraceutical ecosystem. Amid projections of India’s nutritional supplements market reaching USD 68.42 billion by 2030 at a CAGR of 8.0%, the event serves as a critical platform for exploring innovations and opportunities driving the future of health and wellness.

The esteemed expo was graced by distinguished dignitaries, including Chief Guest Dr. Subrata Gupta, IAS, Secretary, Ministry of Food Processing Industries, Govt. of India ; Dr. Manoj Nesari, Advisor, Ayurveda, Ministry of AYUSH, Govt. of India; Mumbai; Dr. Meenakshi Singh, Chief  Scientist, Technology Management Directorate, Council of Scientific & Industrial Research (CSIR); Ms. Natasha Berrow, Executive Vice President – Food, Informa Markets; Mr. Yogesh Mudras, Managing Director Informa Markets in India and Mr. Rahul Deshpande, Sr. Group Director Informa Markets in India among other guests.

Addressing at the event Dr. Subrata Gupta, IAS, Secretary, Ministry of Food Processing Industries, Govt. of India, said “The global nutrition market, valued at approximately $520 billion, is witnessing a growing emphasis on traditional and preventive healthcare. India’s share, estimated around $8 billion, highlights the sector’s vast potential, particularly in Ayurveda-based nutraceuticals. The industry plays a pivotal role in bridging the gap between traditional knowledge and modern healthcare by ensuring accessibility, traceability, and quality of herbal and plant-based products. With increasing global demand, standardization, research-backed validation, and sustainable cultivation practices are critical to strengthening India’s position as a leader in the natural wellness sector. Addressing challenges such as quality planting materials, processing gaps, and export compliance can significantly enhance the sector’s contribution to farmers, employment, and foreign exchange earnings. By leveraging advanced processing techniques like gamma irradiation to improve shelf life and expanding institutional support for small and medium enterprises, India is poised to not only reclaim its 5,000-year-old legacy in Ayurveda but also emerge as a dominant force in the international wellness industry.”

Dr. Manoj Nesari, Advisor, Ayurveda, Ministry of AYUSH, Govt. of India, said, “The Ayurveda and nutraceutical sector is experiencing unprecedented growth, with the market expanding from $3 billion in 2014 to $18.2 billion by 2020 and currently valued at around $24 billion. With a projected target of $200 billion over the next decade, this growth is driven by increasing global acceptance, research advancements, and policy support. The industry is evolving beyond conventional supplements to embrace Ayurvedic Aahar, recognizing the immense potential of flavonoids and alkaloids found in medicinal plants and everyday foods. The thin line between food and medicine highlights the significance of functional ingredients like turmeric, amla, and triphala in promoting holistic well-being. Addressing key public health concerns, such as iron deficiency anemia, requires a shift from mere supplementation to improving nutrient absorption, a focus highlighted by initiatives like Mission Utkarsh. Moreover, amendments to the Food Security Act emphasize the importance of nutrition beyond caloric intake. With Ayurveda extending into veterinary applications and Agro Ayurveda ensuring a sustainable supply chain, India is well-positioned to integrate traditional knowledge with modern health solutions. As global interest in Ayurveda and medical value travel continues to rise, the sector stands at the forefront of fostering both industry growth and societal well-being.”

Salman Mehkri, Head of Business Development, Bio-gen Extracts  “The Indian nutraceutical industry is currently valued at approximately $5–6 billion and is witnessing rapid growth, with a projected CAGR of 12–13%. This strong momentum is expected to double the industry’s size within the next 4–5 years. With increasing consumer awareness, rising disposable incomes, and high-quality products entering the market, we see tremendous potential. The industry has also set an ambitious goal of reaching $100 billion by 2047, coinciding with India’s 100th year of independence. Government support is crucial for accelerating this industry’s expansion. Policies such as reducing the GST on nutraceuticals from the current 18% to a more consumer-friendly 5–12% and introducing PLI-based schemes for manufacturers would enhance affordability and accessibility, especially in tier-2 and tier-3 cities. With the right regulatory and policy support, India’s nutraceutical industry can become a global leader in health and wellness.”

Dr. Meenakshi Singh, Chief Scientist, Technology Management Directorate, Council of Scientific & Industrial Research (CSIR), said “The nutraceutical sector holds immense potential, given India’s rich heritage in botanicals, traditional knowledge, and our leadership in fruits and vegetable production. Recognizing the sector’s challenges, we formed a dedicated task force under the guidance of the Principal Scientific Advisor in 2021, in collaboration with CSIR and key industry leaders. The mission is to address critical gaps, such as the absence of standardized codes for export tracking and regulatory clarity, to foster growth both domestically and globally. We believe that food is not just nourishment but a powerful source of preventive medicine, aiming to reduce healthcare costs through better nutrition. Moving forward, we seek stronger collaboration between industry and research institutions to generate comprehensive scientific data that will propel the nutraceutical industry to new heights.”

Mr. Sanjaya Mariwala, Executive Chairman & Managing Director, OmniActive Health Technologies, said” “India’s rich agricultural potential, coupled with its pharmaceutical expertise, provides a strong foundation for innovation in nutrition, health, and wellness industries. With the right synergy between government policies and industry initiatives, the sector can unlock immense growth opportunities, much like India’s success in the software industry. Given the country’s manufacturing capabilities and scientific talent, achieving a $100 billion market in nutraceuticals is a realistic goal. A focused and collaborative approach can propel India to the forefront of the global nutraceutical landscape, driving industry expansion and enhancing its contribution to global health and wellness.”

Nishant Chachra, Vice President, Business Development, KSM-66 Ashwagandha, said “At KSM-66 Ashwagandha, we take immense pride in being the global leader in Ashwagandha, holding over 67% of all Ashwagandha exports from India. With exports spanning 53 countries, North America remains our largest market, followed by Europe and the Asia-Pacific region. As per NBJ report, Mood and Mental Health is among the fastest-growing condition category in supplements. In 2023, sales increased by 6.9% to hit $1.53 billion and is expected to remain in the 6.5% to 7% range through 2027 driven by increasing consumer demand for mental wellness products addressing anxiety, stress, and cognitive health. As the global demand for Ashwagandha-based solutions rises, we continue to set industry benchmarks with innovation and clinical research, reinforcing our position as the most trusted name in Ashwagandha.”

Speaking on occasion of Vitafoods India 2025, Mr. Yogesh Mudras, Managing Director, Informa Markets in India, said, “Vitafoods India stands as a definitive platform for the nutraceuticals and dietary supplements industry, reflecting its rapid evolution and immense potential. In 2024, the sector experienced remarkable growth driven by consumer demand for personalised and science-backed health solutions, and 2025 is set to build on this momentum. With increasing emphasis on supply chain transparency, digital health integration, and regulatory compliance, stakeholders are well-positioned to address emerging challenges and seize opportunities in this dynamic market. Nutraceuticals now dominate the pharma -supplement market, with evolving regulations like those from FSSAI set to attract investments and foster growth. Vitafoods India continues to play a pivotal role in driving innovation and shaping the future of this thriving industry.”

Vitafoods India 2025 received a strong backing from leading associations, including AHNMI (Association of Herbal and Nutraceutical Manufacturers of India), AFSTI (Association of Food Scientists & Technologists) India (Mumbai Chapter), CASMB (Chamber for Advancement of Small & Medium Businesses), GCCI (The Global Chamber of Commerce & Industry), HADSA (Health Foods and Dietary Supplements Association), SHEFEXIL (Shellac and Forest Products Export Promotion Council) and WIN (Women in Nutraceuticals) .

A key feature of the platform will be its predictive analytics capability, which can identify potential health risks based on dietary patterns and suggest preventive measures directly to patients. These proactive interventions have the potential to be instrumental in optimizing patient outcomes and supporting lasting habit change, marking a shift from reactive to proactive patient care.

Malnutrition poses a significant challenge in hospital environments, affecting patient recovery, outcomes, and readmission rates. Approximately 42% of hospitalized adult patients are malnourished.1 Malnourished hospitalized patients are 56% more likely to be readmitted2 and cost twice as much to treat versus their well-nourished counterparts.3 The Precision Nutrition Platform addresses malnutrition holistically, consistent with emerging gold-standard protocols like Enhanced Recovery after Surgery (ERAS), which puts significant emphasis on nutrition.

Hologram Sciences will develop a new Precision Nutrition Platform for application in clinical settings, integrating Mayo Clinic’s protocols and expertise. The overall platform will leverage Hologram’s personalized nutrition infrastructure, which has been evolving since 2015 to optimize for patient engagement and habit change.

Manpreet S. Mundi, M.D., Medical Director of Clinical Nutrition and an expert in bariatric care at Mayo Clinic, and his team will provide insights to the development process to ready this system for clinical practice.

Clinical Impact of the AI-Enabled Precision Nutrition Platform

The platform intends to provide a dual-interface system, tailored for both patient interaction and physician monitoring. Patients can engage with the platform for customized coaching and feedback, directly impacting their nutritional journey and recovery process. Concurrently, physicians can access a separate interface with the goal of enabling them to closely monitor their patients’ adherence to clinical protocols. The system will alert physicians and clinical staff if direct intervention is needed.

An additional aim of the platform is to enable scalable interactions between Registered Dietitians and patients, which would allow more patients to benefit from their specialized expertise. Combining this personal interaction with a robust nutritional database and a UI that has been fine-tuned to support habit change gives the Precision Nutrition Platform the potential to be a powerful tool in the hands of both patients and healthcare professionals.

First Stress Case: Bariatric Procedures

Initially focusing on bariatric and gastrointestinal surgeries where nutrient absorption is critical, the platform will seek to support patients through pre-surgery preparation and a two-year post-surgery recovery process, offering personalized dietary plans, guidance, and monitoring.

Additional features will include an interactive interface to foster community engagement and provide on-demand access to Registered Dietitians. This human touch seeks to complement the protocol-driven guidance, ensuring a well-rounded patient support system.

Ian Brady, CEO of Hologram Sciences, speaks on the initiative: “Our collaboration with Mayo Clinic is a significant stride in leveraging our technology to personalize patient care. The Precision Nutrition Platform’s goal is to build on our extensive technical capabilities and human insights collected over eight years to meet the intricate nutritional requirements of patients undergoing surgical procedures, ensuring a more successful recovery and long-term wellness.

Danone partners with digital oncology company Resilience for better nutritional care for patients with cancerNutrition information and support during cancer care

According to a recent Ipsos survey commissioned by Danone, 64% of patients with cancer in Europe report nutritional problems that include loss of appetite, dry mouth, and nausea3. These symptoms often lead to weight loss and malnutrition, disrupting treatment plans, and affecting overall quality of life, recovery, and treatment outcomes.

83% of patients deem nutrition an essential topic for their medical care, yet many struggle to identify where to look for advice when they experience eating problems or lose weight. The survey also shows that access to nutritional information during treatment remains irregular. One in four patients say they have not received help or advice in this area, while many do their own research on nutrition. It is crucial to ensure patients have access to credible and timely nutrition advice to support their treatment outcomes.

A partnership at the intersection of digital health and nutrition

Danone is proud to announce a new partnership with Resilience for the development of a nutrition support module for patients with cancer that is now integrated in the Resilience digital oncology solution.

Resilience is a remote patient care solution. Through its platform used by healthcare professionals and its mobile application dedicated to patients with cancer, Resilience combines patient monitoring and tools to help manage treatment-related side effects in a comprehensive solution. Its remote monitoring medical device is now recognized by the French health authorities for all adult patients undergoing systemic cancer treatment. Danone is committed to bringing health through food to as many as possible, also during critical times in life. As a longstanding pioneer in medical nutrition, the company collaborates with healthcare professionals, patient associations and other partners, so that nutrition becomes an integral part of healthcare.

This partnership combines Danone’s expertise about the role of nutrition during illness and health with Resilience’s ability to reinvent patient care and drive the digital healthcare transition. As part of this partnership, Danone’s researchers and medical experts shared findings from peer-reviewed clinical research, and scientific literature and other resources on nutrition during cancer.

Katrien van Laere, Senior VP R&I and Medical Nutritional Science for Danone comments on the partnership: “We are proud to partner with Resilience and share all we have learnt over the years about the role of nutrition in cancer. With partnerships like these we hope to contribute to patient wellbeing and better outcomes for everyone impacted by cancer every day. We are excited Resilience is expanding its digital oncology solutions with evidence-based nutrition modules and screening tools.”

The DRH program will award eight grantees free access to real-world data derived from Komodo’s Healthcare Map, which captures the comprehensive medical, clinical, laboratory, and pharmaceutical encounters of more than 330 million patients. Eligible research projects will focus on topics that facilitate a deeper understanding of the prevalence of diet-related diagnoses such as obesity, diabetes, and cardiovascular disease, as well as treatment for diet-related conditions and barriers to nutrition equity.

“We look forward to seeing how some of our country’s most creative and visionary researchers will leverage Komodo’s real-world data to evolve our collective understanding of diet-related health and disease,” said Katherine Hempstead, Senior Policy Adviser, RWJF.

Komodo Health, RWJF, and Mathematica will host an informational webinar on January 22 at 1 p.m. ET for interested applicants. It will include an overview of the de-identified real-world data that will be available to grantees for analysis within Komodo’s Healthcare Map. The Healthcare Map is accessed exclusively through Komodo’s technology platform and is the industry’s most complete source for assessing disease incidence, understanding patterns and disparities in patient care, and identifying U.S. healthcare system trends and prescribing patterns.

“The Robert Wood Johnson Foundation’s mission to build a Culture of Health drives crucial conversations on some of the most complex health and policy issues facing our nation today, and we are thrilled to contribute to their work by opening up the Healthcare Map for real-world evidence research,” said Web Sun, President and Co-Founder, Komodo Health. “It’s always been Komodo’s goal to reduce the burden of disease, and we are proud to offer grantees a stronger evidence base that can better quantify the effects of diet on health.”

Recipients of the DRH Research Grant are encouraged to submit scientifically rigorous, solution-oriented proposals from investigators representing diverse and/or historically underrepresented disciplines and backgrounds. All applicants must be based in the U.S. or its territories.

The Rheonix C. cayetanensis assay is based on genetic targets developed and published by the FDA and is processed using Rheonix reagents and consumables on the Rheonix Encompass Optimum™ workstation. The study shows the integration and verification of the FDA mitochondrial target into the fully automated and streamlined workstation, which simplifies the workflow by performing DNA isolation, PCR, hybridization, results visualization, and reporting of results. The fully automated method enables detection of low levels of C. cayetanensis in produce samples, saving approximately four hours of hands-on time per 24-sample run, compared with the prior workflow. The assay is now available for use by food and environmental testing laboratories (for more information, please visit the Rheonix website).

Cyclospora cayetanensis is a protozoan parasite that causes cyclosporiasis, a human diarrheal disease. Cases of cyclosporiasis have been observed in the U.S. since the 1990s and have historically been associated with imported fresh food or international travel. During the 2018 cyclosporiasis outbreak investigations, it became clear that produce grown in the U.S. could also be at risk for C. cayetanensis contamination, and over 10,000 domestically acquired cases of cyclosporiasis have been identified since 2018.1 Illnesses and outbreaks caused by C. cayetanensis are associated with the consumption of fresh produce such as herbs, berries, and leafy greens.

The FDA-Rheonix RCA was established in February 2023 to rapidly develop, test, and validate a fully automated screening assay that can detect low levels of C. cayetanensis in fresh produce, soil, and surface agricultural water. Joint development of the assay was announced in June 2023, and addresses the FDA’s Cyclospora Prevention, Response and Research Action Plan priority to “engage with industry, academia, and test kit companies to encourage the modification of available rapid test kits to specifically detect C. cayetanensis, and to develop industry best practices that can be used to test for C. cayetanensis” (Priority Area A2). Both the FDA and Rheonix contributed materials, effort, and subject matter expertise to the collaborative development effort. The assay design addresses a Centers for Disease Control (CDC) proposal that detection assays capture additional Cyclospora species of potential public health concern.

For years, Nestlé has been understanding the the composition of various nutrients and bioactives that are present in breastmilk such as proteins and HMOs.

The company has reported how a specific strain (B. infantis LMG11588) has the ability to efficiently absorb and metabolise HMOs, producing key beneficial compounds, in addition to the direct benefits already provided by the HMOs and the probiotic individually.

Nestlé says that the combination of these elements creates a “synergistic effect,” resulting in a dominance of bifidobacteria which can lead to a more favourable gut environment and stronger immunity in infants.

Building on its expertise, Nestlé has developed the new Sinergity proprietary blend containing an infant-specific probiotic strain along with a blend of HMOs.

As research shows that the composition of HMOs in breastmilk changes during the lactation period, products containing the new blend have varying levels of six different HMOs to meet the specific needs of infants according to age.

Laurent Alsteens, global head of early childhood nutrition at Nestlé, said: “We are absolutely committed to engaging in groundbreaking research and are working with healthcare professionals to contribute to optimal nutrition in early childhood through clinically tested solutions that provide the essential nutrients for babies that cannot be exclusively or who are only partially breastfed. In this way, we can help advance breakthrough nutritional solutions for infants with ingredient blends to support age-appropriate growth, digestive health, bone, muscle and cognitive development and the immune system.”

Isabelle Bureau-Franz, head of Nestlé’s R&D for nutrition, added: “Thanks to our continuous scientific advancements, we have discovered the important benefits of combining our proprietary B. infantis probiotic with a blend of six HMOs. Leveraging our innovation expertise, we developed this breakthrough solution by successfully translating the new scientific findings, scaling-up the production of the probiotic and carefully adapting the levels of six HMOs according to age.”

The new blend has been launched in Hong Kong, with rollout Latin America expected towards the end of the year and in Europe early next year.

The news follows the announcement earlier this week that Nestlé is to shut down its infant formula facility and co-located R&D centre in County Limerick, Ireland, stating that “external trends” have impacted the demand for infant nutrition products in Greater China. Also this week, the company unveiled its first “affordable and nutritious” instant powder in Central and West Africa, combining milk and locally sourced soy, containing essential nutrients such as protein and fibre and providing a source of iron and calcium.

Between NourishedRx and ProHealth Connect, access to food benefits are available through ProHealth Connect-supported flex cards. Individuals can use their flex cards with NourishedRx to purchase nutritious and personalized home-delivered meals and groceries, according to a joint release

“Quality, culturally concordant nutrition has massive untapped potential for improving health and health equity, reinvigorating lives and lifting up communities. The NourishedRx approach upends traditional approaches by using nutritious and delicious food as the doorway for whole health engagement and lasting behavior change,” said Lauren Driscoll, CEO, NourishedRx.

She continued, “By joining ProHealth Connect’s network and integrating with their technology, we have made NourishedRx services more accessible for vulnerable populations across the country. We’re excited to grow this partnership to drive health and health equity – one meal, one individual and one community at a time.”

Registered dietitians oversee NourishedRx’s food recommendations, which are personalized based on the dietary needs and preferences of its members. The integration between NourishedRx’s platform and ProHealth Connect’s API allows for a seamless and efficient experience for members either through an internet connection or over the phone.

“Adding NourishedRx – a world-class digital health and nutrition company – to our offerings is a valuable and important advancement that paves the way for innovation and new solutions that address health equity, nutrition insecurity and diet-related health outcomes in the years again. Now ProHealth has another way to support our members and address food insecurity,” ProHealth Connect’s president, Andrew Winakor, said in a statement.

The intersection between nutrition and healthcare, driven by a combination of machine learning, dietitian support and convenience creates an influential framework for personalized wellness and preventative medicine. With an expected value of $35.89bn by 2030, the personalized nutrition market could potentially address the gap between nutrition and access for individuals who have difficulty accessing or affording health food choices.

​ Foodplant launched its all-in-one meal planning app to help users simplify their meal prep through ChatGPT-driven recipe recommendations. Through the app, users have access to personalized meal plans and recipes based on their dietary preferences. Ingredients from these plans and recipes can be populated into Instacart, allowing users to shop easily for the ingredients they need.

AHARA takes personalized nutrition a step further, categorizing itself as a ​ platform where users’ genetic and health history are integrated into AI-driven meal recommendations and Instacart capabilities. In conjunction with machine learning, AHARA relies on an international advisory board who specialize in epigenetics and nutrition science, among others, to validate the platform’s nutritional support.

Even though nutritional supplements are beneficial, the purpose of consuming them is hardly met if they fail to be available at the body’s target site. In fact, some orally ingested nutrients are not even fully absorbed by the human body. In addition, some supplements when consumed in the conventional form can end up getting damaged by biochemical processes reducing the bioavailability inside the body. The end result is that the supplement becomes ineffective unless it is consumed in large doses, which again is not recommended for fear of unnecessary side effects.

It is for these reasons that there have been several experiments with different techniques to improve the nutrient bioavailability of nutritional supplements. One subject of research that is being studied for several years now is liposomal nanotechnology. This has been used to successfully develop stable and reliable novel drug delivery systems. These systems have been playing a key role in developing applications across a host of medical therapies ranging from HIV to cancer to COVID-19 treatment.

Liposomal Nanotechnology: An Overview

Liposomes are spherically shaped microscopic vesicles consisting of phospholipid bilayer membranes. They are extremely tiny nanoparticles measuring normally up to 100-300 nm in diameter. They are spontaneously formed when certain phospholipids are hydrated with water. These structures have the ability to deliver both hydrophilic and hydrophobic compounds that are used in anti-bacterial, anti-fungal, immune-modulation, diagnostics, ophthalmic, vaccines, enzymes and genetic elements.

Due to the innate nature of these liposomes, it is possible to load both water and fat-soluble active ingredients onto these. These spherical liposome bubbles can be leveraged to trap and stabilize a variety of compounds that are utilized in medications and to ensure their safe passage through the body till these reach a specific target site. Nanotechnology, meanwhile, refers to the process of creating micro particles of the nutrient one wishes to coat with the liposomes.

Role of Liposomal Nanotechnology in Enhancing Benefits of Nutrients

Until recent times, liposomes were only used for targeted drug delivery systems. Nonetheless, they have now found a growing use even in the oral delivery for nutritional supplements and nutraceuticals as well.

Nutraceuticals are often viewed as a simpler and convenient way to describe foods, or their components, that may provide health benefits beyond nutritional food. They contain varied components that affect a number of body functions that are relevant to a state of well-being and health or reduce the risk of a disease.

However, it has been observed that when consumed directly, nutritional supplements are not effective due to their low absorption rate. The nutrient bioavailability is significantly affected because of acidic pH, bile salts, some digestive enzymes, etc, and other elements in the gastrointestinal tract.  This leaves the nutrients ineffective and the therapeutic value that was intended is hardly delivered.

Nanoscience and nanotechnology have the potential to offer innovative solutions in the development of functional foods, especially, the inclusion of bioactive compounds without impacting the sensory perception of the consumer and bettering the acceptance of certain components.

Such advanced nanotechnology approaches are being used to developing high-performance delivery vehicles for the encapsulation and protection of biologically active substances of food origin. This approach makes it possible to load varied nutrients, bioactive ingredients and phytochemicals into biocompatible and biodegradable nanoparticles, that will improve their aqueous solubility, stability, bioavailability, and circulation time in the body.

As soon as the nutrients (either lipophilic or hydrophilic) are encapsulated within the liposomes, they can effectively pass through the metabolism. They can then navigate through the lymphatic pathway in order to get to the small intestine safely and then adhere to the cells there.

More importantly, while liposomes provide protection to the bioactive nutrient, they also make it more stable till the bioactive nutrient molecule is efficiently absorbed by the intestinal epithelia. This helps in ensuring that the bioactive ingredient in the nutritional supplement is absorbed more efficiently by the target cell site, in turn, delivering the full therapeutic value of the nutritional supplement. Liposomes are the best option for the controlled release of many kinds of active ingredients used as nutritional supplements.

As such, for the liposomes to be effectively absorbed by the cell, they must be of a specific size. With the use of nanotechnology and reducing the size of the liposomes to maintain it to around 150nm, the nutrients can be taken up by the cell more effectively.

Let’s understand this better with a few examples of its applications:

Applications in nutritional gummies and chewies

As we saw earlier, nanotechnology refers to the process of creating micro particles of the nutrient one wishes to coat with liposomes. Let us take the example of a Vitamin C chewy or gummies. The micro particles will be inserted into special fat-soluble materials resembling micro bubbles, just a few millionths of an inch in diameter, which have the ability of being absorbed through the gut lining without being digested. The bubbles enter the bloodstream and are presented to the cells of the body as required.

The gut lining accepts the liposomes well because they are made up of a similar material which enhances the body’s capacity to absorb and utilize the nutrient to its fullest potential. The result is that liposomal Vitamin C is absorbed much more efficiently than conventional delivery methods to have maximum bioavailability for the body, resulting in more nutrient being used.

Another advantage is that this process also reduces digestive discomfort, cramping or stomach aches that are common while taking conventional forms of Vitamin C at high doses.

Applications in dermal drug delivery

Another noteworthy use of nanocarriers is for dermal drug delivery. This technology has left a wide field open for research since it enables the penetration of therapeutics across the skin that is a highly complex biological barrier.

In general, dermal drug delivery is generally challenging due to the low skin permeability of therapeutics. While a number of methods have been developed to improve skin penetration and permeation of therapeutics, they are usually aggressive and could lead to irreversible harm.

Nanotechnology represents an alternative approach, with minimal damage to the natural barrier function of skin. In particular, smart nanoparticles that respond to the external environment like temperature and pH have shown promising results for the treatment of multiple dermal disorders.

Techniques Leveraged in Manufacturing Liposomes

Manufacturing techniques have a major role to play in deciding the quality of the liposomes. A range of advanced methods like ethanol injection, thin-film hydration, reverse-phase evaporation and more are used to develop stable liposomes with high encapsulation efficiency.

These methods are a way of ensuring higher encapsulation efficiency and effective drug loading. They also help in the formation of smaller and uniform-size vesicles that result in increased permeation and bioavailability compared to standalone micronutrients.

With the use of these various methods, it is possible to increase the encapsulation efficiency and an effective drug delivery pathway can be established. This in turn enhances the stability of the actives in the nutritional supplements and increases the absorption within the cells.

All in all, liposomes have the ability to become stellar delivery systems owing to their biocompatibility, biodegradability, and low toxicity in the human body. They should be used more often to meet the real needs of the modern nutraceutical industry.

Key Takeaways

Liposomal nanotechnology is likely to make new inroads in the nutraceuticals and functional food industry in the near future. It holds a huge promise to address the limitations that are related to the absorption of a range of nutrients and compounds in the body. In fact, in modern day medicine, the potential of nanotechnology has benefits for a host of areas including cosmetics, food engineering and technology along with nutraceuticals. Moreover, the use of liposomal technology also has a number of seminal applications in the health, sport as well as fitness ecosystem too.

However, its potential notwithstanding, research on oral liposomal formulations is less. There are only a few studies that are looking at research towards the absorption and effects of oral nutritional liposomal formulations on human health.

The nutraceutical industry has not fully unlocked the potential of liposomal nanotechnology. Clearly there is a need for more investments in production technology and product testing besides, research. It is only with an all-round approach will it be possible to ensure the integrity of these products.

About Author

Arun Kedia · Managing Director at VAV Life Sciences

The Issue

According to Lizzy Mulcahy, director of telehealth at the Portland, Maine-based health system, this was pertinent to patient populations in the outpatient program, who needed to be kept connected with their primary care and specialist providers for acute or chronic needs, including for patient populations in the inpatient unit, who were able to receive some of their care virtually.

MaineHealth integrated virtual care services into its care ecosystem to address the need to deliver care virtually, which required recognising and buying the software and hardware solutions, implementing significant patient and care team education initiatives, and creating a process for quality control and analytics, the spokesperson said.

Proposal

MaineHealth sought telemedicine technologies that would be simple to incorporate into its care delivery models and that patients would have easy access to.

IT director for client services and telehealth at MaineHealth, Patty VonIderstine, stated that the solution needs to be able to work efficiently in low-bandwidth areas due to the rurality of Maine. To avoid escalating the hurdles to digital access and digital literacy, selecting a solution that was simple to use for both patients and the care teams was of utmost importance.

Conquering The Trouble

Both inpatient and outpatient settings have employed the telemedicine technology MaineHealth chose. According to telehealth technical architect at MaineHealth, Tom Winchell, in the hospital setting, Vidyo was used to digitally connect care teams with patients in isolation areas. Zoom service access was launched and widely implemented for direct patient care in the outpatient context.

In a fairly short amount of time, around 1,000 licences were implemented, he added. The Zoom capabilities were used for direct patient care among doctors, whether in an office setting or at a distance, with patients who were placed in their own homes and eventually integrated into MaineHealth’s HER.

MaineHealth also bought care team setups, such as desktop PCs, iPads, and web cameras, in order to take part in virtual care.

Results

Utilization has so far been the main success statistic linked to the application of this technology, according to VonIderstine. Care team adoption was widespread; primary care, specialised care, and behavioural health services all had high utilisation rates.

They are still seeing significant amounts of utilisation, especially in the behavioural health sector, she continued. Now that things are moving across to the other side of the pandemic, additionally, group sessions for managing chronic diseases or changing behaviour around a healthy lifestyle have been considered as having a high value for the virtual services.

Using FCC Award Funds

MaineHealth received $803,268 from the FCC telehealth award programme for telemedicine carts, laptops, tablets, and videoconferencing equipment and software that will enable providers to conduct virtual rounds for inpatients, allow patients to see specialised care and primary care providers from the comfort of their own homes, and enable patients in hospitals to use tablets to see and interact with family members they otherwise would be unable to see due to prolonged bed rest.

The FCC CARES program’s resources, according to VonIderstine, enabled a swift rollout of new work processes, modalities, and structure for the delivery of healthcare for the patients of MaineHealth. MaineHealth patients now have access to a strong, comprehensive, and active virtual care option that was not available before the pandemic.

She said, this was planned, bought, tested, deployed, and triggered in a coordinated timetable. The COVID response build-out’s initial phase was able to proceed with better effectiveness and efficiency thanks to CARES’ financial support than would have been otherwise possible. Now that the framework for virtual care has been built, MaineHealth anticipates continuing to expand its omni-channel options for patients and care teams in order to increase the standard of care, enhance the patient experience, and enhance the experience of the care team, she said.

India makes history once more!!, added PM Modi in a tweet. The opposition has accused the prime minister of mishandling the outbreak, which experts claim killed millions of people. The administration disputes the claims.

According to data from the health ministry, 49 deaths were reported overnight, bringing the COVID death toll to 525,709 in the country. The number of new cases increased by 20,528 during the last 24 hours, i.e. between July 16th and July 17th, reaching its highest level since February 20. The majority of COVID-related restrictions have been repealed in the 1.35 billion-strong nation, and global travel has made a strong comeback.

Covishield, a domestically produced vaccine by AstraZeneca, made up about 80% of the immunizations. Others include the Sputnik V from Russia and the locally made Covaxin and Corbevax.

In order to stop the spread of infections, the central government has stepped up its booster campaign, increasing its efforts in the eastern states of Assam and West Bengal, and Karnataka in the south.